A. Roszak

1.4k total citations
82 papers, 721 citations indexed

About

A. Roszak is a scholar working on Epidemiology, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, A. Roszak has authored 82 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 27 papers in Oncology and 24 papers in Obstetrics and Gynecology. Recurrent topics in A. Roszak's work include Endometrial and Cervical Cancer Treatments (24 papers), Ovarian cancer diagnosis and treatment (23 papers) and Cervical Cancer and HPV Research (18 papers). A. Roszak is often cited by papers focused on Endometrial and Cervical Cancer Treatments (24 papers), Ovarian cancer diagnosis and treatment (23 papers) and Cervical Cancer and HPV Research (18 papers). A. Roszak collaborates with scholars based in Poland, United States and Italy. A. Roszak's co-authors include Paweł P. Jagodzińśki, Margarita Lianeri, Anna Sowińska, Piotr Milecki, Adrianna Mostowska, Stefan Sajdak, Katarzyna Hojan, Marta Molińska-Glura, Tudor–Eliade Ciuleanu and Piotr Leszczyński and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

A. Roszak

78 papers receiving 694 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Roszak Poland 15 224 180 166 142 135 82 721
Ingolf Juhasz‐Böss Germany 15 219 1.0× 146 0.8× 117 0.7× 179 1.3× 194 1.4× 87 845
Kosuke Hiramatsu Japan 14 185 0.8× 177 1.0× 169 1.0× 88 0.6× 112 0.8× 58 642
Philip T. Valente United States 16 132 0.6× 133 0.7× 218 1.3× 79 0.6× 165 1.2× 67 744
Kedar Deodhar India 17 316 1.4× 240 1.3× 337 2.0× 79 0.6× 129 1.0× 100 977
Edward R. Kost United States 16 171 0.8× 118 0.7× 272 1.6× 120 0.8× 172 1.3× 48 733
Maria Sotiropoulou Greece 18 181 0.8× 145 0.8× 148 0.9× 45 0.3× 254 1.9× 113 1.0k
Jae Yun Song South Korea 19 233 1.0× 291 1.6× 178 1.1× 70 0.5× 391 2.9× 80 1.1k
Ch. Marth Austria 14 235 1.0× 193 1.1× 67 0.4× 289 2.0× 71 0.5× 50 811
Mary T. Galgano United States 12 138 0.6× 141 0.8× 212 1.3× 32 0.2× 263 1.9× 14 752
K. K. Dhar United Kingdom 14 144 0.6× 183 1.0× 107 0.6× 34 0.2× 148 1.1× 29 602

Countries citing papers authored by A. Roszak

Since Specialization
Citations

This map shows the geographic impact of A. Roszak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Roszak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Roszak more than expected).

Fields of papers citing papers by A. Roszak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Roszak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Roszak. The network helps show where A. Roszak may publish in the future.

Co-authorship network of co-authors of A. Roszak

This figure shows the co-authorship network connecting the top 25 collaborators of A. Roszak. A scholar is included among the top collaborators of A. Roszak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Roszak. A. Roszak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sowińska, Anna, A. Roszak, Margarita Lianeri, et al.. (2023). Role of rs2366152 single-nucleotide variant located in the long noncoding RNA HOTAIR gene in the cervical cancer susceptibility in a Polish population. Journal of Applied Genetics. 65(3). 511–518.
2.
3.
4.
Moore, Kathleen N., Dominique Berton, Gottfried E. Konecny, et al.. (2023). #1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial. A30.1–A30. 1 indexed citations
5.
Hofheinz, Frank, Rafał Czepczyński, Jörg van den Hoff, et al.. (2023). Asphericity derived from [18F]FDG PET as a new prognostic parameter in cervical cancer patients. Scientific Reports. 13(1). 8423–8423. 1 indexed citations
6.
Hofheinz, Frank, Witold Cholewiński, Rafał Czepczyński, et al.. (2021). Prognostic Value of Pretherapeutic Primary Tumor MTV from [18F]FDG PET in Radically Treated Cervical Cancer Patients. Metabolites. 11(12). 809–809. 5 indexed citations
7.
Roszak, A., et al.. (2021). Differences between [18F]FLT and [18F]FDG Uptake in PET/CT Imaging in CC Depend on Vaginal Bacteriology. Diagnostics. 12(1). 70–70. 1 indexed citations
8.
Roszak, A., et al.. (2021). Pretreatment [18F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1. Diagnostics. 11(4). 714–714. 3 indexed citations
9.
Pawlak, Michał, et al.. (2019). The incidence of inflammation among patients suffering from cervix cancer with positive beta haemolytic streptococci cultures from genital tract. Reports of Practical Oncology & Radiotherapy. 24(5). 428–431. 2 indexed citations
10.
Roszak, A., et al.. (2018). Hyperthermia in cervical cancer – current status. Reports of Practical Oncology & Radiotherapy. 23(6). 595–603. 10 indexed citations
11.
Roszak, A., Margarita Lianeri, Anna Sowińska, & Paweł P. Jagodzińśki. (2013). Involvement of PARP-1 Val762Ala Polymorphism in the Onset of Cervical Cancer in Caucasian Women. Molecular Diagnosis & Therapy. 17(4). 239–245. 20 indexed citations
12.
Roszak, A., Margarita Lianeri, & Paweł P. Jagodzińśki. (2012). Prevalence of the NKG2D Thr72Ala Polymorphism in Patients with Cervical Carcinoma. Genetic Testing and Molecular Biomarkers. 16(8). 841–845. 11 indexed citations
13.
Mostowska, Adrianna, et al.. (2011). Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clinical Biochemistry. 44(8-9). 596–600. 41 indexed citations
14.
Kruszyna, Łukasz, et al.. (2010). Distribution of CCND1 A870G Polymorphism in Patients with Advanced Uterine Cervical Carcinoma. Pathology & Oncology Research. 17(1). 133–137. 6 indexed citations
15.
Roszak, A., Mariusz Bidziński, Tudor–Eliade Ciuleanu, et al.. (2009). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Annals of Oncology. 20(11). 1794–1802. 56 indexed citations
16.
Roszak, A., et al.. (2008). Does conformal therapy improve dose distribution in comparison to old techniques in teleradiotherapy of cervical cancer patients?. Reports of Practical Oncology & Radiotherapy. 13(4). 196–201. 4 indexed citations
17.
Szpurek, Dariusz, Stefan Sajdak, Rafał Moszyński, & A. Roszak. (2000). Estimation of neovascularisation in hyperplasia and carcinoma of endometrium using a "power" angio-Doppler technique.. PubMed. 21(4). 405–7. 8 indexed citations
18.
Moszyński, Rafał, et al.. (2000). Estimation of blood flow in uterine arteries using transvaginal colour Doppler ultrasonography in patients with endometrial carcinoma. Nowotwory Journal of Oncology. 50(1). 35–35. 1 indexed citations
19.
Roszak, A., et al.. (2000). 40 Porównanie możliwości i ocena przydatności systemów planowania leczenia BPS 5,0 oraz plato 1,3 firmy Nucletron. Reports of Practical Oncology & Radiotherapy. 5(1). 29–29. 1 indexed citations
20.
Łuczak, J & A. Roszak. (1990). [What patients treated in an oncologic hospital know about their disease].. PubMed. 40(1). 65–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ingolf Juhasz‐Böss Breakdown of academic impact, for papers by Kosuke Hiramatsu Breakdown of academic impact, for papers by Philip T. Valente Breakdown of academic impact, for papers by Kedar Deodhar Breakdown of academic impact, for papers by Edward R. Kost Breakdown of academic impact, for papers by Maria Sotiropoulou Breakdown of academic impact, for papers by Jae Yun Song Breakdown of academic impact, for papers by Ch. Marth Breakdown of academic impact, for papers by Mary T. Galgano Breakdown of academic impact, for papers by K. K. Dhar
Rankless by CCL
2026